They also ensure early detection of emerging problems
Some clinics combine AOD-9604 with GLP-1 drugs for complementary fat loss mechanisms
serum markers (P1NP for bone formation, CTX-1 for resorption) Timepoints: 7 days (inflammatory phase), 14 days (soft callus), 28 days (hard callus), 56 days (remodelling) multiple timepoints essential to characterise mechanism rather than simply endpoint Related Reading: For a comprehensive overview of BPC-157 research, mechanisms, UK sourcing, and safety data, see our BPC-157 UK Complete Research Guide 2026

Table of Contents What Cagrilintide and Retatrutide Are and How They Work Approved Uses and Current Clinical Evidence in the UK How These Medicines May Affect Men Specifically Dosage, Administration, and What to Expect Side Effects, Risks, and Safety Considerations Availability on the NHS and Next Steps for Treatment Scientific References Frequently Asked Questions What Cagrilintide and Retatrutide Are and How They Work Cagrilintide is a long-acting amylin analogue that promotes satiety and slows gastric emptying, while retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors to reduce appetite, enhance insulin secretion, and increase energy expenditure
remains investigational, not approved